Evidence-based policies for new medicines
Electronic versions
Documents
- 03_Ref3b_CaseStudy 1 (Evidence based policies)
113 KB, PDF document
Impact Summary for the General Public
Research at Bangor University’s Centre for Health Economics and Medicines Evaluation has had significant influence on pharmaceutical policy development across the UK. This has impacted directly on the parameters by which the prices of new medicines are to be set in the UK, and how the All Wales Medicines Strategy Group (AWMSG) and the National Institute for Health and Care Excellence (NICE) appraise treatments for rare diseases. Research findings have also defined the methods by which biosimilar medicines are appraised in Wales, and underpinned the Welsh (2012) and Scottish (2013) Governments' decisions against establishing Cancer Drugs Funds.
Category of impact
- Policy and Public Services
Research outputs (4)
- Published
Societal views on NICE, cancer drugs fund and value-based pricing criteria for prioritising medicines: a cross-sectional survey of 4118 adults in Great Britain
Research output: Contribution to journal › Article › peer-review
- Published
HTAs and rare diseases: How to assess their cost-effectiveness
Research output: Contribution to journal › Article › peer-review
- Published
Biosimilars: Evidential standards for health technology assessment.
Research output: Contribution to journal › Article › peer-review